September 2021 - Page 2 of 2 - CanadianCannabisWire

WednesdaySep 15, 2021 12:40 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Making Great Strides Toward Filing IND Application for Patented DehydraTECH(TM) Technology

Lexaria has begun the formal process of preparing an application for Investigational New Drug status for DehydraTECH(TM) and cannabidiol for hypertension The filing is being done with the assistance of an outside consultancy group, with Lexaria Bioscience designing non-clinical, clinical, and related product development required prior to the filing – all of which support Lexaria’s more ambitious goals There have been two successful human hypertension trials done with the combination DehydraTECH-CBD therapy in 2021, following an original human clinical study in 2018, and many animal studies Lexaria is making a strong case to support the efficacy of the technology for…

MondaySep 13, 2021 3:01 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Impressive Blood Pressure Reduction in Hypertension Clinical Trials

Lexaria Bioscience has developed a patented technology that improves the bioavailability of pharmaceuticals and therapeutics in part by bypassing first-pass-liver processing Lexaria’s patented DehydraTECH (TM) technology is undergoing human clinical trials this year to determine its effectiveness in making cannabidiol (“CBD”) effective as a means of reducing blood pressure for high blood pressure patients The initial results of the first human clinical study showed the DehydraTECH-CBD compound was well tolerated by patients without troubling side effects and that the compound outperformed generic CBD controls Just-released initial (partial) results regarding the compound’s second human clinical trial show that a three-dose regimen…

MondaySep 13, 2021 12:27 pm

Flora Growth Corp. (NASDAQ: FLGC) Expands Across International Borders into Europe and Asia

Flora Growth business divisions include pharmaceuticals, cosmetics, hemp textiles, and food & beverage sectors Flora Lab now has three GMP certifications – one each for cosmetics, phytotherapeutic products, and dietary supplements Flora Growth operates internationally but has its cultivation and processing operations based in Colombia – with one of the largest outdoor cultivation facilities in the world, aiming to produce medical-grade cannabis flower and derivative products at below-market pricing Proposed acquisitions of Vessel Brand and Koch & Gsell, as well as investment into Hoshi International, will help expand the business across international borders and into the US, Europe, and Asia…

FridaySep 10, 2021 9:15 am

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Marks Impressive Performance for Q2 2021

$58.5 million in Adjusted Sales for first six months of 2021 The company also reported repaying approximately $18 million of debt and restructuring over $20 million into a long-term debt Q2 also marked RWB’s acquisition of Acreage Florida, as well as an operational 45,000 SF greenhouse within the state, which it projects, will begin harvesting in Q4 2021 RWB’s CEO expressed his optimism about the company’s performance in the Q3 and the second half of the year, given the strides made and the momentum realized in Q2 On August 30, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) released…

FridaySep 10, 2021 9:00 am

RYAH Group Inc. (CSE: RYAH) Publishes Report Outlining Cannabis Treatments for Conditions Associated with HIV and AIDS

RYAH releases report outlining ways cannabis is being used to treat conditions associated with HIV and AIDS Report data compiled by RYAH Data Ecosystem between January 1, 2018, and August 26, 2021 Data includes specific HIV and AIDS conditions, details cannabis strains used by patients Three-part RYAH Data Ecosystem includes volume control and management devices, QR tracking to identify product formulations and parameters, mobile apps to manage information and provide feedback With a mission to advance remote-health solutions and analytics-based patient treatments across the world, RYAH Group (CSE: RYAH) (formerly RYAH Medtech) is the leader in volume control and management…

ThursdaySep 09, 2021 1:27 pm

Flora Growth Corp. (NASDAQ: FLGC) Inks €2M Investment in Hoshi As Part of its European Expansion Plan

Flora closed a €2 million investment in Hoshi International Inc., fulfilling the earlier-announced LOI back in June 2021 This move is set to capitalize on Hoshi’s strong European presence, its technical know-how along with its understanding of the European market Hoshi acknowledged the investment with the announcement that it would work together with Flora to bring to market finished product formats from Flora’s brand portfolio Flora referred to this investment as the first of many steps by the company to advance its plans to launch products across the world On August 24, 2021, Flora Growth (NASDAQ: FLGC) announced closing a…

ThursdaySep 09, 2021 12:57 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Address Advances in its Bioavailability Technology DehydraTECH(TM) at Wainwright Life Sciences Conference

Drug delivery technology innovator Lexaria Bioscience is celebrating the positive outcomes of clinical testing of its trademarked DehydraTECH platform for reducing the blood stream delivery time of anti-virals, NSAIDS and potential hypertension treatments Lexaria will participate in H.C. Wainwright’s annual Global Investor Conference this month to help bring further attention to its successes The DehydraTECH technology enhances the delivery of pharmaceuticals that can be administered orally, and testing has shown no adverse chemical compounds have been created in the process The COVID-19 pandemic has raised the profile of the anti-viral medication market, enhancing the opportunities for Lexaria’s revenue stream As…

WednesdaySep 08, 2021 9:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) is Changing Absorption of Fat-Soluble Compounds Through Patented DehydraTECH(TM) Technology

Lexaria Bioscience Corp. and its patented DehydraTECH technology promote a more effective, less expensive form of oral drug delivery evaluated thoroughly in vivo, in vitro, and human clinical testing DehydraTECH is sub-licensed to other companies in select countries, and is in close collaboration with the largest R&D organization in Canada, the National Research Council, since January 2017 The technology is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter (“OTC”) capsules, pills, tablets, and oral suspensions DehydraTECH-enabled drugs offer multiple benefits, including faster delivery, increased bioavailability, increased brain absorption, improved drug…

ThursdaySep 02, 2021 12:19 pm

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Ideally Situated in Burgeoning Cannabis Beverage Sector

EMR report projects that North America is likely to be fastest, largest marketplace for cannabis beverages Cannabis beverage industry projected to grow at CAGR of 48% in the next five years, reaching an anticipated $12.7 billion by 2026 BevCanna manufactures its own beverage product lines, offers white-label services to companies looking for the highest-quality products available North America will be a leader in the global cannabis beverage market, according to a recent Expert Market Research (“EMR”) report (https://cnw.fm/KFpSc). This projection bodes well for BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health & wellness beverage and natural products…

WednesdaySep 01, 2021 11:21 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets with Drug Delivery Technology

Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral drugs that reach the bloodstream According to a Newsfile Corp. article, this technology can be applied to rendering treatments for HIV/AIDS and other infectious diseases more effective The company also released partial results from a human clinical study evaluating DehydraTECH-processed CBD for potential application against hypertension, which evidenced a rapid and sustained drop in blood pressure Growing hypertension and antiviral therapeutics market represent a potential win for Lexaria In July, Lexaria Bioscience (NASDAQ: LEXX), a drug delivery technology…

News and Publishing Service for Cannabis Related, Canadian Companies

Contact us: 905.674.5977

Month: September 2021